Treatment News : Viread and Epivir Lower Risk of Hepatitis B Infection in HIV-Positive Gay Men

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » April 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


April 15, 2013

Viread and Epivir Lower Risk of Hepatitis B Infection in HIV-Positive Gay Men

Antiretroviral regimens including either Viread (tenofovir) or Epivir (lamivudine or 3TC)  lower the risk of infection with hepatitis B virus (HBV) among HIV-positive gay men who haven’t been vaccinated against hep B, aidsmap reports. Publishing their findings in the online edition of Clinical Infectious Diseases, Japanese researchers examined stored blood samples from 1997 to 2009 of 354 un-vaccinated gay men with HIV who were not infected with hep B. They concluded that both Viread and Epivir could prevent hep B infection and that the drugs lowered the risk of incident risk by up to 90 percent.

Most recommended ARV regimens contain Viread, which is a component of Truvada, Atripla and Complera, or Epivir, which is found in Epzicom and Trizivir.

The men in the study were divided into three categories: those taking an ARV regimen containing Viread or Epivir, those taking different ARVs, and those not on therapy. Within the group, 43 people (12 percent) were newly infected with HBV during the follow-up period. Thirty of those infections were among those not taking ARVs; six were in those taking regimens without Viread or Epivir; and seven infections were among those taking Epivir, with a portion of this group also taking Viread.

The rate of hepatitis B infection was 0.669 per 100 person years for those on either Viread or Epivir, compared with a rate of 6.726 for those not on ARVs and 5.265 for men treated with different ARVs.

The investigators stated that their findings lend support to the argument for treating HIV earlier in the course of infection.

To read the aidsmap story, click here.

To read the study abstract, click here.

Search: Viread, Epivir, hepatitis B, HIV, gay men, tenofovir, Epivir, lamivudine, 3TC, aidsmap, Clinical Infectious Diseases, Truvada, Atripla, Complera, Epivir, Epzicom, Trizivir.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Hide comments

Previous Comments:


[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.